Organization
Amgen, Inc., Deerfield, United States of America
4 abstracts
Abstract
AN ANALYSIS OF RISK FACTORS AND EFFECT OF TREATMENT ON THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITISOrg: The Center for Rheumatology, University of Massachusetts Chan Medical School, Amgen, Inc., Deerfield, United States of America,
Abstract
ACHIEVEMENT OF “GOUT REMISSION” DURING INTENSIVE URATE-LOWERING OVER 52 WEEKS OF PEGLOTICASE THERAPYOrg: Wake Forest University, School of Medicine, Winston-Salem, United States of America, Loma Linda University, School of Medicine, Loma Linda, United States of America, Amgen, Inc., Deerfield, United States of America, Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, United States of America,
Abstract
ASSESSING THE IMPACT OF ETANERCEPT TREATMENT ON PRODUCTIVITY: RESULTS FROM A RECENT RA PATIENT WORK LOSS AND PRODUCTIVITY SURVEYOrg: McKesson Specialty Health, McKesson Corporation, San Francisco Department of Public Health, Global Health Economics and Pricing, Amgen, Inc., Deerfield, United States of America,
Abstract
ASSESSING THE FREQUENCY WITH WHICH RHEUMATOID ARTHRITIS DISEASE ACTIVITY METRICS ARE RECORDED IN COMMUNITY-BASED RHEUMATOLOGY PRACTICES: RESULTS FROM A MEDICAL CHART REVIEWOrg: McKesson Specialty Health, McKesson Corporation, Global Health Economics and Pricing, Amgen, Inc., Deerfield, United States of America,